For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | -4,288 | 23,277 | ||
| Restructuring and impairment | - | 17,486 | ||
| General and administrative | 8,254 | 8,079 | ||
| Total operating expenses | 3,966 | 48,842 | ||
| Operating loss | -3,966 | -48,842 | ||
| Other income | 260 | 860 | ||
| Net loss | -3,706 | -47,982 | ||
| Unrealized (loss) gain on marketable securities | - | -1 | ||
| Other comprehensive (loss) gain | - | -1 | ||
| Comprehensive loss | -3,706 | -47,983 | ||
| Basic EPS | -0.21 | -2.78 | ||
| Diluted EPS | -0.21 | -2.78 | ||
| Basic Average Shares | 17,321,544 | 17,271,518 | ||
| Diluted Average Shares | 17,321,544 | 17,271,518 | ||
Mural Oncology plc (MURA)
Mural Oncology plc (MURA)